WO2019078697A8 - 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 - Google Patents

항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물

Info

Publication number
WO2019078697A8
WO2019078697A8 PCT/KR2018/012492 KR2018012492W WO2019078697A8 WO 2019078697 A8 WO2019078697 A8 WO 2019078697A8 KR 2018012492 W KR2018012492 W KR 2018012492W WO 2019078697 A8 WO2019078697 A8 WO 2019078697A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
pharmaceutical composition
same
cancer treatment
treatment
Prior art date
Application number
PCT/KR2018/012492
Other languages
English (en)
French (fr)
Other versions
WO2019078697A2 (ko
WO2019078697A3 (ko
Inventor
김기수
정준홍
윤애란
송은정
최혜지
임옥재
이윤정
임형권
원종화
Original Assignee
주식회사 녹십자
재단법인 목암생명과학연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA202090944A priority Critical patent/EA202090944A1/ru
Priority to NZ762975A priority patent/NZ762975A/en
Application filed by 주식회사 녹십자, 재단법인 목암생명과학연구소 filed Critical 주식회사 녹십자
Priority to AU2018353787A priority patent/AU2018353787B2/en
Priority to CN201880068391.7A priority patent/CN111315779B/zh
Priority to EP18867685.2A priority patent/EP3699192A4/en
Priority to CA3077007A priority patent/CA3077007C/en
Priority to MX2020003947A priority patent/MX2020003947A/es
Priority to JP2020521940A priority patent/JP7024072B2/ja
Priority to SG11202003273PA priority patent/SG11202003273PA/en
Priority to US16/754,431 priority patent/US11498965B2/en
Priority to BR112020007770-4A priority patent/BR112020007770A2/pt
Publication of WO2019078697A2 publication Critical patent/WO2019078697A2/ko
Publication of WO2019078697A3 publication Critical patent/WO2019078697A3/ko
Publication of WO2019078697A8 publication Critical patent/WO2019078697A8/ko
Priority to IL274007A priority patent/IL274007A/en
Priority to US17/958,995 priority patent/US20230192851A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 항-CD3 항체 및 이를 포함하는 암 치료용 약학적 조성물에 관한 것이다. 본 발명의 항체는 CD3에 대한 높은 친화도 (affinity) 및 특이성 (specificity)을 가지므로, 암의 예방 또는 치료에 효과적으로 사용될 수 있다.
PCT/KR2018/012492 2017-10-20 2018-10-22 항" cd3항체 및 이를포함하는 암치료용 약학적 조성물 WO2019078697A2 (ko)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SG11202003273PA SG11202003273PA (en) 2017-10-20 2018-10-22 Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
JP2020521940A JP7024072B2 (ja) 2017-10-20 2018-10-22 抗ｃｄ３抗体およびそれを含む癌処置用医薬組成物
AU2018353787A AU2018353787B2 (en) 2017-10-20 2018-10-22 Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same
NZ762975A NZ762975A (en) 2017-10-20 2018-10-22 Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
EP18867685.2A EP3699192A4 (en) 2017-10-20 2018-10-22 ANTI-CD3 ANTIBODIES AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT WITH IT
CA3077007A CA3077007C (en) 2017-10-20 2018-10-22 Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
US16/754,431 US11498965B2 (en) 2017-10-20 2018-10-22 Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same
EA202090944A EA202090944A1 (ru) 2017-10-20 2018-10-22 Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
CN201880068391.7A CN111315779B (zh) 2017-10-20 2018-10-22 抗-cd3抗体及包含其的用于癌症治疗的药物组合物
MX2020003947A MX2020003947A (es) 2017-10-20 2018-10-22 Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
BR112020007770-4A BR112020007770A2 (pt) 2017-10-20 2018-10-22 anticorpo anti-cd3, uso do mesmo para prevenção ou tratamento de câncer, composição farmacêutica compreendendo dito anticorpo, polinucleotídeo, vetor de expressão, célula hospedeira e método para produção de um anticorpo que se liga especificamente ao cd3
IL274007A IL274007A (en) 2017-10-20 2020-04-16 Anti-CD3 antibody and a pharmaceutical preparation containing it for the treatment of cancer
US17/958,995 US20230192851A1 (en) 2017-10-20 2022-10-03 Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170136564A KR101973060B1 (ko) 2017-10-20 2017-10-20 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
KR10-2017-0136564 2017-10-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/754,431 A-371-Of-International US11498965B2 (en) 2017-10-20 2018-10-22 Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same
US17/958,995 Division US20230192851A1 (en) 2017-10-20 2022-10-03 Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same

Publications (3)

Publication Number Publication Date
WO2019078697A2 WO2019078697A2 (ko) 2019-04-25
WO2019078697A3 WO2019078697A3 (ko) 2019-07-04
WO2019078697A8 true WO2019078697A8 (ko) 2020-04-09

Family

ID=66173409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012492 WO2019078697A2 (ko) 2017-10-20 2018-10-22 항" cd3항체 및 이를포함하는 암치료용 약학적 조성물

Country Status (14)

Country Link
US (2) US11498965B2 (ko)
EP (1) EP3699192A4 (ko)
JP (1) JP7024072B2 (ko)
KR (1) KR101973060B1 (ko)
CN (1) CN111315779B (ko)
AU (1) AU2018353787B2 (ko)
BR (1) BR112020007770A2 (ko)
CA (1) CA3077007C (ko)
EA (1) EA202090944A1 (ko)
IL (1) IL274007A (ko)
MX (1) MX2020003947A (ko)
NZ (1) NZ762975A (ko)
SG (1) SG11202003273PA (ko)
WO (1) WO2019078697A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236797A1 (en) * 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
JP2023543826A (ja) * 2020-09-29 2023-10-18 イノベント バイオロジクス（シンガポール）プライベート リミティド 抗ｃｄ３抗体およびその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537219A2 (en) * 2002-03-26 2005-06-08 Trubion Pharmaceuticals, Inc. Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb
EP3770174A1 (en) * 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EP2710042A2 (en) * 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
BR122016016837A2 (pt) 2011-05-21 2019-08-27 Macrogenics Inc moléculas de ligação a cd3; anticorpos de ligação a cd3; composições farmacêuticas; e usos da molécula de ligação a cd3
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN113248615A (zh) 2013-07-05 2021-08-13 根马布股份公司 人源化或嵌合cd3抗体
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
DK3736292T3 (da) * 2013-12-17 2024-07-22 Genentech Inc Anti-CD3-antistoffer og fremgangsmåder til anvendelse
AU2015283704A1 (en) * 2014-07-01 2016-12-15 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
KR20180104157A (ko) * 2016-02-04 2018-09-19 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 인간화 항-cd3 항체, 접합체 및 이의 용도
WO2018199593A1 (ko) * 2017-04-24 2018-11-01 재단법인 목암생명과학연구소 Her3 및 cd3에 결합하는 이중특이적 항체

Also Published As

Publication number Publication date
EP3699192A2 (en) 2020-08-26
IL274007A (en) 2020-05-31
CN111315779B (zh) 2024-06-21
JP7024072B2 (ja) 2022-02-22
EA202090944A1 (ru) 2020-07-16
AU2018353787B2 (en) 2022-02-24
CA3077007C (en) 2023-04-18
AU2018353787A1 (en) 2020-05-21
US20230192851A1 (en) 2023-06-22
BR112020007770A2 (pt) 2020-10-20
NZ762975A (en) 2024-07-26
WO2019078697A2 (ko) 2019-04-25
KR101973060B1 (ko) 2019-04-26
WO2019078697A3 (ko) 2019-07-04
US11498965B2 (en) 2022-11-15
CN111315779A (zh) 2020-06-19
MX2020003947A (es) 2020-08-03
SG11202003273PA (en) 2020-05-28
EP3699192A4 (en) 2021-10-20
US20200317779A1 (en) 2020-10-08
CA3077007A1 (en) 2019-04-25
JP2021501571A (ja) 2021-01-21

Similar Documents

Publication Publication Date Title
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
PH12021550152A1 (en) Anti-cd112r compositions and methods
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2018016364A (es) Anticuerpos anti-pd-l1.
PH12016501680B1 (en) Anti-egfrviii antibodies and uses thereof
WO2018191548A3 (en) Complement factor d antagonist antibodies and conjugates thereof
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12020500225A1 (en) Anti- cd137 antibodies
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
SA519401424B1 (ar) Cmet عوامل ربط أحادية النسيلة، مترافقات عقار منها واستخداماتها
WO2019078698A3 (ko) 항 -msln항체 및 이를포함하는 암치료용 약학적 조성물
WO2019078697A8 (ko) 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18867685

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3077007

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020521940

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018353787

Country of ref document: AU

Date of ref document: 20181022

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018867685

Country of ref document: EP

Effective date: 20200520

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020007770

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020007770

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200417